BioLineRx (BLRX) Tops Q2 EPS by 7c

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• Driven Brands (DRVN) Tops Q4 EPS by 2c, Misses on Revenue; Offers FY26 Guidance
• Oracle results beat estimates, but shares fall on plans for $40 billion raise